Why Summit Therapeutics Stock Rocketed 6% Higher on Friday

Source The Motley Fool

Summit Therapeutics (NASDAQ: SMMT) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors snapped it up to push its price nearly 6% higher across the day's trading session. That performance well outpaced that of the benchmark S&P 500 index; this only bumped 0.3% higher.

Initiated with a buy

Jefferies, in the person of analyst Hangfei Fu, launched its Summit coverage with a confident buy recommendation and a price target of $31 per share. That's a robust 67% higher than the stock's most recent closing price.

According to reports, Fu's highly bullish take is focused on ivonescimab, a cancer drug from Chinese biotech Akeso that Summit is developing in the hopes of bringing it to market outside of the Asian country to treat lung cancer. Fu pointed out the encouraging results of the drug in recent testing and said it could hit approximately $10 billion in sales if approved.

Ivonescimab has done rather well in head-to-head clinical trials against a top cancer drug, Merck's Keytruda. That alone has attracted much investor attention and helped propel Summit's share price higher.

Room for growth

So the question is, could it go higher still? At this stage, it seems that Summit is in a fine position with ivonescimab, which is showing many signs of being a potential blockbuster on the market. We should bear firmly in mind, however, that the path to regulatory approval -- especially in this country -- is long and difficult, and never guaranteed. Typical for biotech stocks, Summit is a play for those with an above-average tolerance for risk.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $376,143!*
  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $46,028!*
  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $494,999!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of December 2, 2024

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Jefferies Financial Group, Merck, and Summit Therapeutics. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
Nov 16, Mon
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
Nov 17, Tue
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 18, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
Author  Mitrade
Yesterday 03: 33
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
placeholder
US Dollar Index Price Forecast: DXY could target 104.00 as bulls await FOMC MinutesThe US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
Author  FXStreet
19 hours ago
The US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 19, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
Author  Mitrade
2 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
goTop
quote